/BLMS

BLMS Stock - Bloomios, Inc.

Q: What is the analyst price target for BLMS?

Analyst price target information is not currently available for BLMS.

Q: What is BLMS's market cap?

Market capitalization information is not currently available for BLMS.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BLMS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.78

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$6.08M	$8.49M	$1.32M	N/A	N/A
Gross Profit	$2.23M	$3.78M	$401,545	N/A	N/A
Gross Margin	36.7%	44.5%	30.5%	N/A	N/A
Operating Income	$-4,140,000	$-800,000	$-1,063,000	$-16,863	$-10,000
Net Income	$-13,774,000	$-2,011,000	$-1,171,000	$-16,863	$-10,000
Net Margin	-226.7%	-23.7%	-89.0%	N/A	N/A
EPS	$-1.04	$-0.16	$-0.09	$-0.00	$-0.00

Company Overview

Bloomios, Inc. manufactures, markets, and distributes cannabidiol products. The company's product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. It sells its hemp derived supplements and cosmetic products through wholesale and retail distribution channels. The company was formerly known as XLR Medical Corp. and changed its name to Bloomios, Inc. in April 2021. Bloomios, Inc. was incorporated in 2001 and is headquartered in Santa Barbara, California.

Visit Website

Earnings History & Surprises

BLMS

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.42

Q3 2023

EPS Surprise History

Q4 22

No data

Q1 23

No data

Q2 23

No data

Q3 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2023	Sep 30, 2023	—	$-0.42	—	—
Q2 2023	Jun 30, 2023	—	$-0.09	—	—
Q1 2023	Mar 31, 2023	—	$-0.19	—	—
Q4 2022	Dec 31, 2022	—	$-0.57	—	—

Frequently Asked Questions about BLMS

What is BLMS's current stock price?

Bloomios, Inc. (BLMS) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for BLMS?

No analyst price targets are currently available for this stock.

What sector is Bloomios, Inc. in?

Bloomios, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is BLMS's market cap?

Bloomios, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does BLMS pay dividends?

No, Bloomios, Inc. does not currently pay a dividend to shareholders.